Skip to main content
Home > Week in Review > Deals

Chronological Index of BioCentury, Week in Review: Deals

BioCentury, Week in Review Current Issue
  • SkyePharma, Theravance, GlaxoSmithKline deal

    SkyePharma plc (LSE:SKP), London, U.K. Theravance Inc. (NASDAQ:THRX), South San Francisco, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Drug delivery, Pulmonary SkyePharma said that it is …

    Published on 5/20/2013
  • Theragenics, Juniper Investment Company LLC deal

    Theragenics Corp. (NYSE:TGX), Buford, Ga. Juniper Investment Company LLC, New York, N.Y. Business: Supply/Service, Other Theragenics said it received a proposal from investment firm Juniper to acquire all outstanding …

    Published on 5/20/2013
  • Tianjin Pharmaceuticals Group Co. Ltd., Vectura deal

    Tianjin Pharmaceuticals Group Co. Ltd., Tianjin, China Vectura Group plc (LSE:VEC), Chippenham, U.K. Business: Inflammation, Pulmonary Vectura partnered with Tianjin Pharmaceuticals' Tianjin KingYork Group Co. Ltd. …

    Published on 5/20/2013
  • UCB, IBM Corp. deal

    UCB Group (Euronext:UCB), Brussels, Belgium IBM Corp. (NYSE:IBM), Armonk, N.Y. Business: Bioinformatics IBM and UCB partnered to develop a point-of-care analytics system to predict the probability of success of epilepsy…

    Published on 5/20/2013
  • Vanda, Bristol-Myers deal

    Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Washington, D.C. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Neurology Vanda disclosed in its 1Q13 earnings that Bristol-Myers Squibb waived its option to …

    Published on 5/20/2013
  • AbCheck, Daiichi Sankyo deal

    AbCheck s.r.o., Plzen, Czech Republic Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Business: Antibodies, Cancer AbCheck will use its AbSieve phage and yeast display technologies to discover antibodies …

    Published on 2/25/2013
  • Advanced Cell Technology, International Stem Cell deal

    Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica, Calif. International Stem Cell Corp. (OTCBB:ISCO), Carlsbad, Calif. Business: Cell/Gene therapy Advanced Cell and International Stem Cell amended a 2004 deal to …

    Published on 2/25/2013
  • Alexion deal

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Business: Hematology Alexion recommended shareholders reject an unsolicited mini-tender offer by investment firm TRC Capital Corp. to acquire up to 1.5 million…

    Published on 2/25/2013
  • Amgen, Selexis deal

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Selexis S.A., Geneva, Switzerland Business: Biomanufacturing The companies expanded a 2004 R&D license to grant Amgen non-exclusive rights to use Selexis' SURE CHO-M cell …

    Published on 2/25/2013
  • Andrus Reo, Oncolytics deal

    Andrus Reo Ltd., Moscow, Russia Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY), Calgary, Alberta Business: Cancer Oncolytics granted Andrus Reo rights in Russia and the Commonwealth of Independent States (CIS) to …

    Published on 2/25/2013
  • AquaBounty, Intrexon deal

    AquaBounty Technologies Inc. (LSE:ABTX), Maynard, Mass. Intrexon Corp., Blacksburg, Va. Business: Agbio/Environmental Intrexon and aquaculture company AquaBounty partnered to use Intrexon's UltraVector synthetic biology…

    Published on 2/25/2013
  • Biogen Idec, Merck, Samsung Group deal

    Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Samsung Group, Seoul, South Korea Business: Biosimilars Merck partnered with Samsung Bioepis Co. Ltd. to develop and …

    Published on 2/25/2013
  • Biomedical Structures, TissueGen Inc. deal

    Biomedical Structures LLC, Warwick, R.I. TissueGen Inc., Dallas, Texas Business: Drug delivery The companies partnered to develop a finished textile platform for drug-eluting medical devices using TissueGen's fiber-…

    Published on 2/25/2013
  • BioNTech, 4SC deal

    BioNTech AG, Mainz, Germany 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Business: Cancer 4SC's 4SC Discovery GmbH subsidiary will identify and optimize small molecule anti-cancer drugs against undisclosed targets …

    Published on 2/25/2013
  • Caliber Biotherapeutics, iBio deal

    Caliber Biotherapeutics LLC, Bryan, Texas iBio Inc. (NYSE-M:IBIO), Newark, Del. Business: Cancer, Biomanufacturing iBio granted Caliber a non-exclusive license to use iBio's iBioLaunch plant-based vaccine and …

    Published on 2/25/2013
  • Cangene, Inspiration Biopharmaceuticals, Ipsen deal

    Cangene Corp. (TSX:CNJ), Winnipeg, Manitoba Inspiration Biopharmaceuticals Inc., Cambridge, Mass. Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Business: Hematology Cangene acquired Inspiration's …

    Published on 2/25/2013
  • Cepheid, Oregon Health & Science University deal

    Cepheid Inc. (NASDAQ:CPHD), Sunnyvale, Calif. Oregon Health & Science University, Portland, Ore. Business: Diagnostic Cepheid partnered with the university's Knight Cancer Institute to develop molecular cancer …

    Published on 2/25/2013
  • Champions Oncology, Teva deal

    Champions Oncology Inc. (OTCBB:CSBR), Baltimore, Md. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Cancer Champions (formerly Champions Biotechnology Inc.) received a one-time $880,000 …

    Published on 2/25/2013
  • Chiesi, Cornerstone Therapeutics deal

    Chiesi Farmaceutici S.p.A., Parma, Italy Cornerstone Therapeutics Inc. (NASDAQ:CRTX), Cary, N.C. Business: Pulmonary Cornerstone said its board received a proposal from partner Chiesi to take Cornerstone private. Chiesi…

    Published on 2/25/2013
  • China Shenghuo Pharmaceutical Holdings Inc., Lan's Int'l Medicine Investment Co. Ltd. deal

    China Shenghuo Pharmaceutical Holdings Inc. (Pink:CKUN), Kunming, China Lan's Int'l Medicine Investment Co. Ltd., Kunming, China Business: Pharmaceuticals China Shenghuo said its board received from Lan's a proposal to …

    Published on 2/25/2013
  • ConfometRx, UCB deal

    ConfometRx, Santa Clara, Calif. UCB Group (Euronext:UCB), Brussels, Belgium Business: Neurology UCB and structural biology company ConfometRx partnered to research GPCR modulation to discover new therapies for …

    Published on 2/25/2013
  • Galectin Therapeutics, University of Georgia deal

    Galectin Therapeutics Inc. (NASDAQ:GALT), Norcross, Ga. University of Georgia, Athens, Ga. Business: Cancer, Inflammation Galectin and the university's Complex Carbohydrate Research Center partnered to discover …

    Published on 2/25/2013
  • Illumina, Verinata deal

    Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Verinata Health Inc., Redwood City, Calif. Business: Diagnostic Illumina completed its acquisition of prenatal testing company Verinata for $350 million, plus up to $100 …

    Published on 2/25/2013
  • Isis Pharmaceuticals, KineMed, CHDI Foundation Inc. deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. KineMed Inc., Emeryville, Calif. CHDI Foundation Inc., New York, N.Y. Business: Neurology Isis will use biomarkers from KineMed and the not-for-profit foundation…

    Published on 2/25/2013
  • Lotus Tissue Repair, Shire deal

    Lotus Tissue Repair Inc., Cambridge, Mass. Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Dermatology Shire disclosed in its 2012 earnings that it completed the acquisition of Lotus Tissue Repair for an …

    Published on 2/25/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?